US
CA
NZ
UK
AU
IND
Last update at 2025-07-14T13:30:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
GRFS or NBIX: Which Is the Better Value Stock Right Now?
Thu 15 May 25, 03:40 PMHigh Growth Tech Stocks in Europe for May 2025
Wed 07 May 25, 05:38 AMAustralia's CSL evaluates China tariff exemptions for its US-made drugs
Wed 30 Apr 25, 10:17 AMHere’s White Falcon’s Views on Grifols, S.A. (GRFS)
Mon 28 Apr 25, 12:40 PMExploring High Growth Tech Stocks In Europe April 2025
Tue 08 Apr 25, 10:08 AMBrookfield resumes Grifols takeover talks, El Confidencial reports
Wed 02 Apr 25, 07:03 AMIs Grifols, S.A. (GRFS) the Best Low Price Pharma Stock to Invest In Right Now?
Thu 27 Feb 25, 02:16 PMGrifols SA (GIFLF) (Q4 2024) Earnings Call Highlights: Record Revenues and Strategic ...
Thu 27 Feb 25, 11:00 AMExploring High Growth Tech Stocks In February 2025
Tue 04 Feb 25, 02:03 PMGotham, Grifols Eye Two Separate Regulator Reports Ahead of Legal Standoff
Wed 22 Jan 25, 03:22 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 361.26M | 350.45M | 878.63M | 817.10M | 725.84M |
| Minority interest | -62.86700M | -82.52400M | 1611.66M | 2023.65M | 471.05M |
| Net income | 208.28M | 182.80M | 708.99M | 625.15M | 596.64M |
| Selling general administrative | 1190.42M | 1061.51M | 985.62M | 942.82M | 814.77M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 2231.53M | 1962.60M | 2255.16M | 2341.23M | 2049.56M |
| Reconciled depreciation | 407.86M | 359.77M | 321.53M | 302.45M | 228.61M |
| Ebit | 704.16M | 595.62M | 1037.60M | 1187.44M | 977.97M |
| Ebitda | 1112.03M | 955.39M | 1359.13M | 1489.89M | 1206.58M |
| Depreciation and amortization | 407.86M | 359.77M | 321.53M | 302.45M | 228.61M |
| Non operating income net other | - | - | - | 0.00000M | 0.00000M |
| Operating income | 805.68M | 595.06M | 996.13M | 1131.37M | 994.12M |
| Other operating expenses | 5361.77M | 4370.61M | 4364.70M | 3976.30M | 3492.60M |
| Interest expense | 362.63M | 233.81M | 222.92M | 324.38M | 274.16M |
| Tax provision | 90.11M | 85.13M | 169.64M | 168.46M | 131.44M |
| Interest income | 33.86M | 11.55M | 8.02M | 114.20M | 13.99M |
| Net interest income | -462.66500M | -266.44300M | -241.61800M | -228.76800M | -279.27800M |
| Extraordinary items | - | - | - | 0.00000M | 0.00000M |
| Non recurring | - | - | - | 0.00000M | 0.00000M |
| Other items | - | - | - | 0.00000M | 0.00000M |
| Income tax expense | 90.11M | 85.13M | 169.64M | 168.46M | 131.44M |
| Total revenue | 6063.97M | 4933.12M | 5340.04M | 5098.69M | 4486.72M |
| Total operating expenses | 1529.33M | 1400.09M | 1279.83M | 1218.84M | 1055.44M |
| Cost of revenue | 3832.44M | 2970.52M | 3084.87M | 2757.46M | 2437.16M |
| Total other income expense net | 121.72M | 54.39M | 144.91M | -76.52200M | 11.00M |
| Discontinued operations | - | - | - | 0.00000M | 0.00000M |
| Net income from continuing ops | 271.15M | 265.33M | 708.99M | 648.64M | 594.41M |
| Net income applicable to common shares | 208.28M | 182.80M | 618.55M | 625.15M | 596.64M |
| Preferred stock and other adjustments | - | - | - | 0.00000M | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 21533.98M | 19233.83M | 15274.78M | 15542.61M | 12477.05M |
| Intangible assets | 2949.15M | 1636.95M | 1557.65M | 1433.53M | 1385.54M |
| Earning assets | - | - | - | - | - |
| Other current assets | 81.81M | 64.08M | 51.75M | 58.11M | 42.34M |
| Total liab | 13076.43M | 11086.80M | 8554.72M | 8696.84M | 7780.44M |
| Total stockholder equity | 6129.94M | 6096.64M | 5108.39M | 4822.12M | 4225.55M |
| Deferred long term liab | 1622.64M | 633.24M | 575.51M | 331.81M | 287.20M |
| Other current liab | 504.82M | 407.60M | 389.97M | 453.24M | 411.71M |
| Common stock | 119.60M | 119.60M | 119.60M | 119.60M | 119.60M |
| Capital stock | 119.60M | 1030.33M | 1030.33M | 1030.33M | 1030.33M |
| Retained earnings | 208.28M | 182.80M | 618.55M | 488.32M | 459.89M |
| Other liab | 2051.73M | 682.36M | 627.75M | 544.20M | 502.61M |
| Good will | 7011.91M | 6228.90M | 5332.27M | 5507.06M | 5209.23M |
| Other assets | 1930.41M | 882.61M | 812.55M | 564.25M | 505.43M |
| Cash | 547.98M | 655.49M | 579.65M | 741.98M | 1033.79M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1955.85M | 3474.31M | 1335.14M | 1366.56M | 1257.32M |
| Current deferred revenue | 37.83M | 43.54M | 23.98M | 10.64M | 15.53M |
| Net debt | 9202.15M | 8668.81M | 6331.75M | 6364.91M | 5254.91M |
| Short term debt | 681.27M | 2394.18M | 319.57M | 320.80M | 268.20M |
| Short long term debt | 578.92M | 2345.61M | 276.93M | 276.40M | 264.85M |
| Short long term debt total | 9750.12M | 9324.31M | 6911.40M | 7106.89M | 6288.71M |
| Other stockholder equity | 748.51M | 746.54M | 866.99M | 861.14M | 855.29M |
| Property plant equipment | 4168.49M | 3343.15M | 3002.80M | 2863.40M | 1951.98M |
| Total current assets | 4653.59M | 5510.28M | 3164.95M | 5362.18M | 3483.25M |
| Long term investments | 2548.89M | 2359.97M | 1980.06M | 143.98M | 228.82M |
| Net tangible assets | -2208.47700M | -1135.96800M | -1206.01400M | -1786.67000M | -2082.00800M |
| Short term investments | 43.26M | 2029.11M | 10.86M | 1727.43M | 0.82M |
| Net receivables | 754.82M | 495.48M | 504.20M | 470.50M | 401.57M |
| Long term debt | 8154.26M | 6104.97M | 5900.97M | 6089.80M | 6010.97M |
| Inventory | 3201.36M | 2259.35M | 2002.28M | 2342.59M | 1949.36M |
| Accounts payable | 731.92M | 628.99M | 601.62M | 581.88M | 561.88M |
| Total permanent equity | - | - | - | 0.00000M | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | 0.00000M | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | 0.00000M | 0.00000M |
| Accumulated other comprehensive income | 5053.55M | 5047.70M | 3503.25M | 3353.05M | 2790.77M |
| Additional paid in capital | - | - | - | 0.00000M | 0.00000M |
| Common stock total equity | - | - | - | 0.00000M | 0.00000M |
| Preferred stock total equity | - | - | - | 0.00000M | 0.00000M |
| Retained earnings total equity | - | - | - | 0.00000M | 0.00000M |
| Treasury stock | - | - | - | 0.00000M | 0.00000M |
| Accumulated amortization | - | - | - | 0.00000M | 0.00000M |
| Non currrent assets other | 54.06M | 4.14M | - | 10180.43M | 211.37M |
| Deferred long term asset charges | - | - | - | 0.00000M | 0.00000M |
| Non current assets total | 16880.39M | 13723.56M | 12109.82M | 10180.43M | 8993.80M |
| Capital lease obligations | 1016.94M | 873.72M | 733.50M | 740.69M | 12.88M |
| Long term debt total | - | - | - | 0.00000M | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -1978.82300M | 9.82M | -27.23800M | -31.81600M | 37.16M |
| Change to liabilities | 80.21M | 40.45M | -2.31900M | -44.54400M | 135.26M |
| Total cashflows from investing activities | -1978.82300M | -29.39300M | -858.11500M | -548.78900M | -781.86700M |
| Net borrowings | -177.37200M | 1878.52M | -243.37300M | -7.51500M | 37.42M |
| Total cash from financing activities | -173.49300M | 1472.92M | -354.40100M | -332.35600M | 152.50M |
| Change to operating activities | -9.01000M | -7.07500M | -20.60000M | -13.87100M | -3.09200M |
| Net income | 361.26M | 350.45M | 878.63M | 817.10M | 725.84M |
| Change in cash | -2127.63200M | 2095.96M | -162.33500M | -291.81000M | 147.27M |
| Begin period cash flow | 2675.61M | 579.65M | 741.98M | 1033.79M | 886.52M |
| End period cash flow | 547.98M | 2675.61M | 579.65M | 741.98M | 1033.79M |
| Total cash from operating activities | -10.86700M | 596.98M | 1110.34M | 568.93M | 737.43M |
| Issuance of capital stock | - | - | - | - | 0.00000M |
| Depreciation | 407.86M | 359.77M | 321.53M | 302.45M | 228.61M |
| Other cashflows from investing activities | - | - | - | 0.00000M | 0.00000M |
| Dividends paid | -0.59200M | -258.94600M | -113.23000M | -238.74000M | 278.84M |
| Change to inventory | -600.24500M | -157.47400M | 164.63M | -323.74800M | -231.67000M |
| Change to account receivables | -80.17000M | -16.80600M | -35.42900M | -99.37400M | -13.14100M |
| Sale purchase of stock | -3.45900M | -125.70300M | - | 0.00000M | 0.00000M |
| Other cashflows from financing activities | -65.15500M | 1940.26M | 110.74M | 33.98M | 573.28M |
| Change to netincome | -17.79100M | 195.31M | 63.97M | 122.87M | 24.82M |
| Capital expenditures | 375.56M | 315.09M | 362.56M | 412.31M | 307.72M |
| Change receivables | - | - | - | 0.00000M | 0.00000M |
| Cash flows other operating | - | - | - | 0.00000M | 0.00000M |
| Exchange rate changes | - | - | - | 0.00000M | 0.00000M |
| Cash and cash equivalents changes | - | - | - | 0.00000M | 0.00000M |
| Change in working capital | -609.21900M | -140.90800M | 106.28M | -481.53700M | -112.63900M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | -170.76900M | 27.66M | -196.10900M | -69.08800M | -104.38400M |
| Free cash flow | -386.42700M | 281.89M | 747.78M | 156.63M | 429.71M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GIFOF Grifols S.A |
- -% | 8.81 | 231.75 | 9.57 | 1.38 | 0.94 | 3.13 | 31.98 |
| LLY Eli Lilly and Company |
-21.12 2.64% | 778.22 | 78.14 | 31.95 | 16.34 | 45.83 | 16.65 | 54.36 |
| JNJ Johnson & Johnson |
-1.645 1.05% | 155.18 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
-6.225 3.25% | 185.29 | 61.52 | 14.86 | 5.62 | 51.62 | 6.76 | 20.58 |
| MRK Merck & Company Inc |
-2.191 2.62% | 81.48 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Avinguda de la Generalitat, 152, Barcelona, Spain, 08174
| Name | Title | Year Born |
|---|---|---|
| Mr. Steven Francis Mayer J.D. | Exec. Chairman | 1960 |
| Mr. Raimon Grifols Roura | Co-CEO & Exec. Director | 1964 |
| Mr. Víctor Grifols Deu | Co-CEO & Exec. Director | 1977 |
| Mr. Alfredo Arroyo Guerra | CFO & VP | 1958 |
| Mrs. Eva Bastida Tubau | Corp. VP and Director of Scientific & Medical Affairs | NA |
| Ms. Nuria Pascual Lapeña | VP of Corp. Treasury, Risk Management Investor Relation & Sustainability Officer | 1964 |
| Mr. David Ian Bell | Gen. Counsel & Chief Corp. Devel. Officer | 1954 |
| Mr. Mateo Florencio Borrás Humbert | Corp. VP & Chief HR Officer | 1956 |
| Ms. Maria Teresa-Rioné Llano | Chief Communications Officer | 1965 |
| Ms. Montserrat Gaja Llamas | Chief HR Officer | 1965 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...